Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,100.93
(
-0.35%
)
US TECH 100
25,848.00
(
-0.41%
)
Dow Jones
49,379.60
(
-0.14%
)
Brent Oil
91.37
(
-1.39%
)
Bitcoin
76,240.51
(
3.22%
)
News Focus
News Focus
Post# of 257430
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122879
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 78561

Thursday, 05/28/2009 1:54:43 AM

Thursday, May 28, 2009 1:54:43 AM

Post# of 257430

I believe Botox is already extensively off-label used in spasticity but perhaps it will be further reimbursed.

The penetration of Botox in spasticity is already respectable for an off-label indication, but spasticity is not currently a major contributor to total Botox sales in all indications. As you noted, FDA approval should greatly help with reimbursement.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today